Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 26, 2022 (5 years ago)

Peppermint Antacid tablet

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Peppermint Antacid tablet (Calcium Carbonate 420 mg) Bulk Container, ULTRAtab Laboratories, Inc., Highland, NY NDC 62959-303-00

Affected NDC 62959-0303-00

Compare with the code on your package — it is the most precise check available.

Recalling firm
ULTRAtab Laboratories, Inc.
NDC code
62959-303-00
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0539-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by ULTRAtab Laboratories, Inc.

All 2022 recalls
Class II · Moderate risk

Cystex Tablet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. D-0555-2022

Other cgmp deviation recalls from 2022

All cgmp deviation recalls